These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 10578011)

  • 1. Recovery of coronary flow and left ventricular function after abciximab.
    Mak KH; Neumann FJ; Blasini MR; Schmitt MC; Alt ME; Dirschinger MJ; Gawaz MM; Kastrati MA; Schömig MA
    Circulation; 1999 Nov; 100(22):e110. PubMed ID: 10578011
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction.
    Neumann FJ; Blasini R; Schmitt C; Alt E; Dirschinger J; Gawaz M; Kastrati A; Schömig A
    Circulation; 1998 Dec; 98(24):2695-701. PubMed ID: 9851955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: the horizons-AMI CMRI substudy.
    Wöhrle J; Merkle N; Kunze M; Cristea E; Mehran R; Rottbauer W; Stone GW
    Catheter Cardiovasc Interv; 2012 Jun; 79(7):1083-9. PubMed ID: 22162175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG Investigators
    N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
    Montalescot G; Barragan P; Wittenberg O; Ecollan P; Elhadad S; Villain P; Boulenc JM; Morice MC; Maillard L; Pansiéri M; Choussat R; Pinton P;
    N Engl J Med; 2001 Jun; 344(25):1895-903. PubMed ID: 11419426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction associated with thrombotic occlusion of the left main coronary artery.
    Rechavia E; Wurzel M
    Circulation; 1998 Sep; 98(12):1249-50. PubMed ID: 9743517
    [No Abstract]   [Full Text] [Related]  

  • 7. Abciximab improves 6-month clinical outcome after rescue coronary angioplasty.
    Petronio AS; Musumeci G; Limbruno U; De Carlo M; Baglini R; Paterni G; Grazia Delle Donne M; Caravelli P; Nardi C; Mariani M
    Am Heart J; 2002 Feb; 143(2):334-41. PubMed ID: 11835040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of bivalirudin with heparin versus abciximab with heparin for primary percutaneous coronary intervention in "Real World" practice.
    Showkathali R; Davies JR; Parker M; Taggu W; Tang KH; Clesham GJ; Gamma RA; Sayer JW; Aggarwal RK; Kelly PA
    Cardiovasc Revasc Med; 2013; 14(5):289-93. PubMed ID: 23972537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycoprotein inhibitors and fibrinolysis in myocardial infarction.
    Ring BL
    JAMA; 2000 Dec; 284(24):3124-5. PubMed ID: 11135766
    [No Abstract]   [Full Text] [Related]  

  • 10. Platelet GP IIb/IIIa inhibition in myocardial infarction treated by coronary stenting: ready for prime time.
    Anderson HV
    J Invasive Cardiol; 2000 Mar; 12(3):140-1. PubMed ID: 10877555
    [No Abstract]   [Full Text] [Related]  

  • 11. Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators.
    Kereiakes DJ; Lincoff AM; Miller DP; Tcheng JE; Cabot CF; Anderson KM; Weisman HF; Califf RM; Topol EJ
    Circulation; 1998 Mar; 97(9):857-64. PubMed ID: 9521334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Parmar R; Stouffer GA
    Am J Med Sci; 1997 Jul; 314(1):31-6. PubMed ID: 9216438
    [No Abstract]   [Full Text] [Related]  

  • 13. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
    Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ
    Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects on thrombin generation of the platelet glycoprotein IIb/IIIa inhibitors abciximab versus tirofiban during coronary intervention.
    Ambrose JA; Doss R; Geagea JM; Hawkey MC; Duvuri S; Giedd K; Dominguez A; Coppola J; Nguyen TH; Palla V; Barua RS; Saha DC
    Am J Cardiol; 2001 May; 87(10):1231-3: A8. PubMed ID: 11356410
    [No Abstract]   [Full Text] [Related]  

  • 15. Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? No.
    Ragosta M; Sarembock IJ
    J Thromb Haemost; 2004 Jan; 2(1):10-2. PubMed ID: 14717959
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of GP IIb/IIIa inhibitors on vascular inflammation, coronary microcirculation, and platelet function.
    Kereiakes DJ
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S3-11. PubMed ID: 17224889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ;
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine use of abciximab in coronary stenting?
    Stables RH
    Lancet; 1998 Jul; 352(9122):81-2. PubMed ID: 9672267
    [No Abstract]   [Full Text] [Related]  

  • 19. Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials.
    De Luca G; Suryapranata H; Stone GW; Antoniucci D; Tcheng JE; Neumann FJ; Bonizzoni E; Topol EJ; Chiariello M
    J Am Coll Cardiol; 2006 Feb; 47(3):685-6. PubMed ID: 16458158
    [No Abstract]   [Full Text] [Related]  

  • 20. Glycoprotein IIb/IIIa inhibitors: current indications and future prospects.
    Reginelli JP; Topol EJ
    Am J Med; 2000 Aug; 109(3):252-4. PubMed ID: 10974193
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.